Conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO by Gilles-Eric Séralini et al.
Séralini et al. Environmental Sciences Europe 2014, 26:13
http://www.enveurope.com/content/26/1/13COMMENTARY Open AccessConflicts of interests, confidentiality and
censorship in health risk assessment: the example
of an herbicide and a GMO
Gilles-Eric Séralini1,2*, Robin Mesnage1,2, Nicolas Defarge1,2 and Joël Spiroux de Vendômois2Abstract
We have studied the long-term toxicity of a Roundup-tolerant GM maize (NK603) and a whole Roundup pesticide
formulation at environmentally relevant levels from 0.1 ppb. Our study was first published in Food and Chemical
Toxicology (FCT) on 19 September, 2012. The first wave of criticisms arrived within a week, mostly from plant biologists
without experience in toxicology. We answered all these criticisms. The debate then encompassed scientific arguments
and a wave of ad hominem and potentially libellous comments appeared in different journals by authors having serious
yet undisclosed conflicts of interests. At the same time, FCT acquired as its new assistant editor for biotechnology a
former employee of Monsanto after he sent a letter to FCT to complain about our study. This is in particular why FCT
asked for a post-hoc analysis of our raw data. On 19 November, 2013, the editor-in-chief requested the retraction of our
study while recognizing that the data were not incorrect and that there was no misconduct and no fraud or intentional
misinterpretation in our complete raw data - an unusual or even unprecedented action in scientific publishing. The
editor argued that no conclusions could be drawn because we studied 10 rats per group over 2 years, because they
were Sprague Dawley rats, and because the data were inconclusive on cancer. Yet this was known at the time of
submission of our study. Our study was however never attended to be a carcinogenicity study. We never used the
word ‘cancer’ in our paper. The present opinion is a summary of the debate resulting in this retraction, as it is a historic
example of conflicts of interest in the scientific assessments of products commercialized worldwide. We also show that
the decision to retract cannot be rationalized on any discernible scientific or ethical grounds. Censorship of research
into health risks undermines the value and the credibility of science; thus, we republish our paper.
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There is an ongoing debate on the potential health risks
of the consumption of genetically modified (GM) plants
containing high levels of pesticide residues [1]. Currently,
no regulatory authority requests mandatory chronic ani-
mal feeding studies to be performed for edible GMOs and
formulated pesticides. This fact is at the origin of most of
the controversies. Only studies consisting of 90-day rat
feeding trials have been conducted by manufacturers for
GMOs. Statistical differences in the biochemistry of
treated rats versus controls may represent the initial signs* Correspondence: criigen@criigen.info
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in any medium, provided the original work is pof long-term pathologies [2], possibly explained at least in
part by pesticide residues in the GM feed. This is why we
studied the long-term toxicity of a Roundup-tolerant GM
maize (NK603) and a whole Roundup pesticide formula-
tion at environmentally relevant levels from 0.1 ppb.
We first published these results in Food and Chemical
Toxicology (FCT) on 19 September, 2012 [3] after a care-
ful and thorough peer review. However, 1 year and
2 months later, in an unusual step, the editor-in-chief re-
quested the retraction of our study, while conceding that
the data were not incorrect and that there was no mis-
conduct and no fraud or intentional misinterpretation.
According to him, some data were inconclusive, but for
reasons already known at the time of submission of the
paper. The present paper is a summary of the debate
resulting in this retraction, which in our view is aan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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assessments of products commercialized worldwide.
The long-term toxicity study of the NK603 maize
and Roundup
An initial study on NK603 maize was submitted by
Monsanto Company in support of commercial authoriza-
tion of the maize. NK603 maize was fed to 4 groups of 20
Sprague Dawley rats (2 doses of 11% and 33% in the diet
of both sexes) for 90 days [4]. The blood analyses were
performed on 10 rats per group. The re-analysis of the
raw data resulted in a debate on the biological relevance
of admitted statistical differences versus controls as
the first signs of hepatorenal toxicities [5]. To solve the
problem, a 2-year-long study was carried out using two
hundred Sprague Dawley rats to which the following treat-
ments were administered: NK603 maize treated or not
with Roundup at three different levels in their feed (11%,
22%, and 33% of the total diet) and Roundup alone, ad-
ministered via drinking water at three different concentra-
tions, from the admitted residual level in regular tap water
(0.1 ppb), to the maximum level authorized in GMOs
(400 ppm), up to half of the agricultural dose (0.5%). They
were divided into ten groups, each containing ten males
and ten females. No other long-term study has examined
the effects of regular consumption of Roundup-tolerant
GM maize and of a pesticide formulation, in any dilution,
on blood parameters, sexual hormones, and multiple
organs.
We found that these products provoked statistically
discriminant disturbances in biochemical markers of
livers and kidneys in females at the 15th month, when
most of the rats were still alive. At the same time, testos-
terone and estradiol levels were also disturbed. At the
end of the experiments, these disrupted biochemical
markers corresponded to pathologies evidenced in a
blinded manner: notably hepatorenal deficiencies, more
severe in males, and female mammary tumors, which
led to premature deaths. For instance, after around
700 days, there were up to 3.25 more mammary tumors
(the highest rate was observed in females consuming
0.1 ppb of Roundup in water). This could be associated
with a 2.4-time increase in pituitary dysfunctions noticed
by the end of the experiment (2 years).
These findings were immediately dismissed by persons
involved in the products’ authorizations, or in collabor-
ation with biotech industries. A number of them wrote
to FCT to nourish a controversy, including Richard
Goodman, a former Monsanto employee in charge of
the immunotoxicity files of GMOs, and Paul Christou, a
patent holder of the methods used to create transgenic
plants. This was rapidly followed by a coordination of
national regulatory agencies organized by the European
Food Safety Authority (EFSA), released on 4 October,2012 [6]. The EFSA had previously assessed NK603, and
glyphosate, the declared active principle of Roundup, as
safe on the basis of regulatory data, which they never
fully published. The EFSA has since published Monsanto’s
safety data on NK603 maize [7], but not on glyphosate.
The NK603 data are in a pdf format preventing an easy
statistical re-analysis. However, there was no long-term
toxicological assessment for NK603, or for Roundup.
Moreover, we demonstrated in several studies [8-10] that
Roundup is far more toxic than glyphosate because of
non-inert adjuvants. On 10 October, 2012, the Monsanto
Company also sent its criticisms to FCT [11] but did not
release its safety data, claiming commercial confidentiality.
Overall, the first wave of criticisms arrived within a
week, mostly from plant biologists. We answered all
criticisms [12] in FCT on 9 November, 2012. The debate
then encompassed scientific arguments. A second wave
of ad hominem and potentially libelous comments ap-
peared in different journals [13-16]. Regrettably, there
were no invitations to respond to these exacerbated at-
tacks, which we discovered only by our literature survey.
Some of the authors of these articles had serious yet
undisclosed conflicts of interest. The scientific remarks
concentrated on the supposedly inadequate choice of the
Sprague Dawley rat strain, which is, however, a classic
model for toxicology [17]. The Sprague Dawley strain
was also used by Monsanto in its 90-day test on the
same maize [4]. In addition, Monsanto measured bio-
chemically the same number of rats per group as in our
experiment. Thus, with regard to blood and urine bio-
chemistry, Monsanto gathered data from the same num-
ber of rats that we did.
Unsubstantiated allegations of fraud or errors
Paul Christou, the lead author of Arjo et al. [13],
demanded that our paper be retracted and insulted us
personally. He claimed first in a letter addressed to the
editor-in-chief that the publication of our study ‘does not
meet minimal acceptable standards of scientific rigor’
and ‘will damage an entire scientific discipline due to
flawed conclusion’ (personal communication). Then, he
attacked us in an article published in the journal Trans-
genic Research on 20 December 2012 [13]. The quantity
of insults and defamations in this paper, authorized and
co-authored by the editor-in-chief in a supposedly ser-
ious journal, is excessive. They include: ‘abject failure to
treat the experimental animals in a humane manner’,
‘inability to formulate a valid hypothesis’, ‘media fanfare’,
‘fraudulent or knowingly inaccurate statements’, ‘uneth-
ical behavior’, ‘transparent attempt to discredit regulatory
agencies’, ‘ammunition for extremists’, ‘flawed science’, ‘dis-
ingenuous or inept’, and ‘unjustified waste of animals’
(while at the same time asking for more animals in the
groups). Christou and co-authors suggest that by practising
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better quality of life’ and in fact are ‘actively working to
make life worse’. We were not invited to reply. This behav-
iour can be explained, though not justified, by the undis-
closed conflicts of interests.
Christou is not only the editor-in-chief of Transgenic
Research, the journal in which he published his article,
but is also linked to Monsanto [18]. He is named as the
inventor on several patents on GM crop technology, for
most of which Monsanto owns the property rights. These
include patents on the plant transformation process [19]
used to make glyphosate-tolerant transgenic corn plants
[20]. He worked as a researcher at Agracetus Inc. (later
acquired by Monsanto) for 12 years. Then, from 1994 to
2001, Christou worked at the John Innes Centre in the
UK [18], which is heavily invested in GM crop technology
[21]. He thus has no mammalian toxicology background.
However, in his published article, Christou only gave as
his affiliation his publicly funded position at a research
institute. Christou’s failure to declare his current inter-
ests - his inventor status on patents concerning the
company that developed the products we tested - could
be considered grounds for retraction of a paper in a
scientific journal, according to ethical guidelines for
scientific publishing [22].
The Arjo et al. article was co-authored by Wayne
Parrott, an active member of the Biotechnology Com-
mittee at the International Life Sciences Institute (ILSI)
[23]. ILSI is funded by multinational food, agribusiness,
and biotechnology companies, including Monsanto and
Syngenta [24]. ILSI has proved highly controversial in
North America and Europe due to its influence on risk
assessment methodologies for chemicals, pesticides, and
GM foods [25-27]. Wayne Parrott also has an inventor
status in patents on materials and methods for selecting
transgenic organisms [28] and transformation vector
systems [29].
In addition, Christou and his co-authors made numer-
ous mistakes, false and unsubstantiated assertions, and
misrepresentations of our data. The title of Arjo et al.’s
paper includes defamation and a misrepresentation of
our research, implying that it is ‘pseudoscience’ and
alleging that it claimed Roundup Ready maize and
Roundup herbicide caused ‘cancer’ in rats - a claim we
never made. We did not even use the word ‘cancer’ in
our paper although this argument was reiterated in the
final letter of the editor-in-chief of FCT when explaining
his decision to retract our paper [30]. Tumors do not al-
ways lead to cancer, even if they can be more deleterious
in a shorter time because of their size or body position,
by hurting internal functions.
Arjo et al.’s paper begins with a false assertion that is
not evidenced in the paper or in the cited source: ‘It
started with a press conference in which journalistsagreed not to engage in fact-checking’. The authors made
other false assertions about our study, for example, al-
leging that ‘the water consumption was not measured’. In
fact, we measured both the water and food consumption,
and the stability of the Roundup solution over time. This
was indicated in the paper, in which we explained that all
the data cannot be shown in one paper and that we con-
centrated on the most important data; these parameters
were only part of a routine survey. They also falsified the
reporting of the data, compiling the mortality data only at
the end of the experiment and ignoring the originality and
the major findings of the differential chronological effects
between treated rats and controls, which we established
by measuring tumor size twice a week over 2 years. More-
over, we respected legal requirements and ethical norms
relating to animal experiments, and Arjo et al. present no
evidence of the contrary, so their allegation of inhumane
treatment of the rats is without substance.
Importantly, we had already answered many of the
criticisms of our paper made by Arjo et al. in a paper
that was published before that of Arjo et al. [12]. Their
publication was received on 20 December 2012, when
our paper was published on 9 November 2012. Our
published answers were simply ignored.
Christou was not alone in failing to declare conflicts of
interest in his criticism of our paper. Since we under-
lined that 75% of the comments addressed to FCT
within a week after our study was published came from
plant biologists, it was discovered that several had devel-
oped patents on GMOs. Some authors were employees
of Monsanto Company, which owns NK603 GM maize
and sells Roundup herbicide [4,11]. Other more recent
papers, published by plant biologists and/or affiliates of
the industry-funded group ILSI [15,16], repeated the ar-
guments. The author of a separate article criticizing our
study expressed concern that our results could damage
public opinion about GM crops [14] - a sentiment that
gives precedence to economic interests over public
health. An article in Forbes magazine even alleged, with-
out presenting any evidence, that we had committed
fraud [31]. Surprisingly, even Monsanto authors [11] de-
clared that they had ‘no conflicts of interest’ in their first
draft published online on FCT website. Investigative
reports [32,33] evidenced that many authors of these
opinions had failed to disclose their conflicts of interest,
including Henry Miller, Mark Tester, Chris Leaver, Bruce
Chassy, Martina Newell-McGloughlin, Andrew Cockburn,
L. Val Giddings, Sivramiah Shantharam, Lucia de Souza,
Erio Barale-Thomas, and Marc Fellous. The undisclosed
conflicts of interest included links with biotechnology
companies that develop GMOs and with industry-backed
lobbying organizations.
All of this has huge implications for public health. We
observed an intense lobbying in parliaments, as well as
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the regulatory decisions for the commercialization of
these products [26]. A series of high-profile conflict-of-
interest revelations (not restricted to GMOs and pesti-
cides) led to the resignations of leading administrators
involved in decisions affecting the assessment of these
products, including the European Commissioner John
Dalli [34] and the former chair of the European Food
Safety Authority’s (EFSA) management board Diana
Banati [35]. In February of 2013, a strange occurrence
following the publication of our paper raised questions
about the connections of industry to scientific publish-
ing, described below.
Conflicts of interests in the editorial board
In February 2013, FCT acquired a new assistant editor
for biotechnology, Richard E. Goodman. The editor-in-
chief has admitted that Goodman was introduced into
the editorial board after he sent a letter to FCT to com-
plain about our study. In his letter, Goodman appears
worried about economic consequences but not so much
about potential public health consequences (personal
communication). He wrote: ‘The implications and the
impacts of this uncontrolled study is having HUGE im-
pacts, in international trade, in consumer confidence in
all aspects of food safety, and certainly in US state refer-
endums on labelling’. Further in his letter, Goodman
asked for ‘an evaluation by an independent set of toxicol-
ogists’. This is particularly why the Publishing Assistant
for FCT asked for our raw data on 15 March 2013.
In fact, we can question the independence of this re-
evaluation. After his appointment at FCT, Goodman was
a member of the subcommittee that requested our raw
data, until we complained to Elsevier publishing group.
Goodman is far from being independent. He previously
worked for Monsanto for 7 years [36]. He also has a
long-standing affiliation with ILSI [37]. Goodman will
now deal with all biotechnology papers submitted to
FCT. Another scientific paper on GMO risks was with-
drawn from FCT, without explanation shortly after it
had been accepted and published by the journal [38].
The paper was immediately published by another journal
[39] according to the authors’ initiative.
We received a letter from the editor-in-chief of FCT,
A. Wallace Hayes, asking us to retract our paper on 19
November 2013, more than 1 year after its publication
[40]. In his retraction notice, the editor-in-chief certifies
that ‘no evidence of fraud or intentional misrepresenta-
tion of the data’ was found in the investigation, that the
results are ‘not incorrect’, ‘there was no misconduct’, and
that the sole reason for retraction is the ‘inconclusive-
ness’ of the paper. He argued that no conclusions could
be drawn because we studied 10 rats per group over
2 years, because they were Sprague Dawley rats, andbecause we could not conclude on cancer. In fact, the
Sprague Dawley is a standard choice for 2-year studies
performed by industry and independent scientists alike
[17,41]. We also measured 10 animals per sex per group
according to OECD 452 guideline on chronic toxicity
studies [42] because our study is a chronic toxicity study
that was never intended to be a carcinogenicity study.
We wish to point out that Dr Hayes’ decision is in viola-
tion of the retraction guidelines of the Committee on
Publication Ethics (COPE), of which FCT is a member.
‘Inconclusiveness’ is not a valid reason for a journal to re-
tract a paper. Lack of conclusiveness (which can be dis-
cussed) and error are not synonymous. COPE criteria
for retraction included scientific misconduct/honest
error, prior publication, plagiarism, or unethical re-
search. None of these criteria applied to our study. On
the contrary, numerous published scientific papers con-
tain inconclusive findings. It is for further studies to
build on the reported findings and arrive at a more con-
clusive position. In contrast with our study measuring
toxicity, the Monsanto study reporting safety with the
same number and the same strain of rats, but limited to
90 days, [4] is not subject to the same controversy. The
data in the Monsanto study show statistically significant
differences in multiple-organ functions between the GM
and non-GM feeding groups, which the authors dis-
missed as not ‘biologically meaningful’, using a set of
questionable criteria [43]. The significant effects ob-
served do not have to be linear to the dose to be taken
into consideration; otherwise, endocrine effects will be
dismissed. In addition, biochemical disturbances do not
have to correlate simultaneously with organ lesions, in
contrast to the claims of Doull et al. [44] in defence of
Monsanto. These outdated concepts coming from the
toxicology of poisons, and are not valid for endocrine
disruption [43,45]. If 10 rats/sex/group are too few to
demonstrate a toxic effect, then this number of rats is
certainly too small to demonstrate safety. Overall, in the
current system of assessment, any toxic effect is first
suspected to be a false positive, arising by chance, rather
than questioning whether no evidence of effect is a false
negative result. The Monsanto data as presented are
thus inconclusive and should also be retracted.
Following the retraction of our paper, many letters
were sent to the editor-in-chief of FCT. On 10 December
2013, he published a defence of the retraction, which
raised many doubts as to his understanding of our data
[30]. He claimed that we concluded on cancer, although
ours was a long-term toxicity study with a detailed statis-
tical analysis of blood and urine parameters. He also
defended the study done by Monsanto [4] claiming that
they used 20 rats/sex/group while we only used 10 rats/
sex/group. In fact, despite the fact that the Monsanto
study used twice our sample size, the Monsanto authors
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(10), the same number of sampled animals as in our study.
According to an editorial in Environmental Health
Perspectives [46], ‘the decision to retract a published
scientific work by an editor, against the desires of the
authors, because it is ‘inconclusive’ based on a post hoc
analysis represents a dangerous erosion of the underpin-
nings of the peer-review process, and Elsevier should
carefully reconsider this decision’.
Confidentiality and censorship erode the value
of science
Recent reviews of the GM food safety literature have
found that research concluding that GM products were
safe tended to come from industry and that research con-
ducted by those with either financial or professional con-
flicts of interest was associated with outcomes favorable to
the GM sector [47]. In fact, it appears in our case that
consequences of conflicts of interests in science go beyond
divergence in scientific interpretations and also rely on
unscientific practices: confidentiality and censorship.
Transparency of, and access to, all the raw data ob-
tained by companies and accepted by regulatory agencies
(overall blood analyses of rats) as proof of safety for
products, is an unavoidable first step to move forward in
this debate. It is the only way in which the scientific
community can enter the scientific discussion. This is
why we republish our paper in an open access way,
together with its raw data allowing debate about our
results. This is not possible for the data used as a proof
of safety for commercial authorizations. The Monsanto
toxicological data on NK603 maize recently made public
by EFSA is not in a statistically usable format and an
agreement with Monsanto is requested before use.
Moreover, the data examined for Roundup authoriza-
tions are clearly inadequate [48]. For instance, ANSES
(French Agency for Food, Environmental and Occupa-
tional Health & Safety), confirmed to us in writing
(January 2013) that there were no 2-year studies of
Roundup in its whole formulation on animals, adding
that there are a few studies of acute toxicity (a few days
up to 3 weeks) without any blood tests. Instead, glypho-
sate, which is much less toxic than Roundup [10,49], is
tested alone by Monsanto, in its reports to regulatory
authorities [50]. We strongly emphasize that data with
implications for public health are not related to manu-
facturing patents and should not be kept confidential.
Removal of confidentiality claims on biosafety data is
necessary to adhere to standard scientific procedures of
quality assurance, to increase transparency, to minimize
impacts of conflicts of interests, and ultimately to im-
prove public confidence in GMOs [51]. Moreover, in the
regulatory assessment of GMOs, chemicals, and medi-
cines, confidential tests are conducted by the applicantcompanies themselves, often in their own laboratories or
in those of subcontractors.
The second step must be the building of new experi-
ments for new or the most important products, by
laboratories independent of the companies. They will be
recruited by public tender, with compulsory transpar-
ency of the results. This public research will be funded
by companies, at a level corresponding to their previous
budget for regulatory testing, but managed independ-
ently of the companies. The protocols and results will be
submitted to open and contradictory assessments. Thus,
there will be no additional financial cost or time delay to
the current system. Such reforms will not only radically
transform the understanding and knowledge of toxicol-
ogy and science in general, but will radically reduce pub-
lic health costs and promote trust in companies and
science. This will move the world towards a sustainable
development of products with low, if any, impacts on
health and environment.
The reason given to retract our paper - ‘inconclusiveness’ -
is unprecedented and violates the norms of scientific pub-
lishing. The decision to retract cannot be rationalized on
any discernible scientific grounds. Censorship on research
into the risks of a technology so critically entwined with
global food safety undermines the value and the credibility
of science.
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